

Special Issue

Treatment Strategies and Emerging Biomarkers in High-Risk Early-Stage Melanoma

Message from the Guest Editors

Melanoma remains an aggressive disease. Although patients with melanoma are most frequently diagnosed with early stage disease, they are at high risk for recurrence and subsequent death even after surgical resection, the current standard of care. Thus, increased awareness and research efforts for the management of these early-stage melanoma patients are urgently needed.

For this Special Issue, we are pleased to invite you to contribute original research articles or reviews regarding the molecular landscape of stage II–III melanoma and potential targets for treatment. We also welcome research, including basic, translational, and clinical studies, on novel approaches for the characterization and management of this subset of melanoma patients. Submissions may also recount the history of early-stage melanoma and the evolution of clinical data specific to this group.

This Special Issue aims to provide insight on the prognostic and clinical limitations that exist with traditional histopathologic and staging methods for early stage melanoma patients and call for approaches that may lead to better patient outcomes.

We look forward to receiving your contributions.

Guest Editors

Dr. Yvonne M. Saenger

Albert Einstein College of Medicine, Montefiore Medical Center, New York, NY 10461, USA

Prof. Dr. Larisa J. Geskin

Department of Dermatology, Columbia University, New York, NY 10032, USA

Deadline for manuscript submissions

closed (20 January 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/176098

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)